Amantadine

Generic Name: Amantadine

Brand Names: Gocovri, Osmolex

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₇N

CAS Number: 768-94-5

Unique Ingredient Identifier: BF4C9Z1J53

Background: An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps ...

Indication: For the chemoprophylaxis, prophylaxis, and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Also for the treatment of parkinsonism and drug-induced extrapyramidal reactions.

Associated Conditions: Dyskinesia, Extrapyramidal disorder caused by neuroleptic drugs without Tardive dyskinesia, Influenza A Virus Infection, Parkinson's Disease (PD), Parkinson's Disease With Wearing-off Motor Fluctuations, Parkinsonism

Associated Therapies: -

Clinical Trials

Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection

Recruiting

Conditions: COVID19
ACE Inhibitors
Antihistamine Allergy
Amantadine
ARB
Influenza Vaccination

Interventions: Drug: Antihistamine
Drug: Amantadine
Drug: ACEI
Drug: ARB
Other: Influenza vaccine and COVID

First Posted Date: 2020-04-29

Last Posted Date: 2024-04-26

Lead Sponsor: Consorci Sanitari de Terrassa

Target Recruit Count: 3000

Registration Number: NCT04367883

Locations: 🇪🇸
Hospital de Terrassa, Terrassa, Barcelona, Spain

Effects of Amantadine on Postoperative Cognitive Dysfunction

Not Applicable

Conditions: Postoperative Cognitive Dysfunction

Interventions: Drug: Amantadine

First Posted Date: 2018-05-17

Last Posted Date: 2019-01-03

Lead Sponsor: Zhiyi Zuo

Target Recruit Count: 390

Registration Number: NCT03527134

Locations: 🇨🇳
Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China

Citicholine-Amantadine Trial in Traumatic Brain Injury

Phase 4

Completed

Conditions: Intensive Care Unit

Interventions: Drug: Citicholine
Drug: Amantadine

First Posted Date: 2018-02-13

Last Posted Date: 2024-05-24

Lead Sponsor: Ain Shams University

Target Recruit Count: 45

Registration Number: NCT03430817

Locations: 🇪🇬
Ain Shams University hospitals, Cairo, Egypt

Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis

Phase 3

Completed

Conditions: Fatigue in Multiple Sclerosis

Interventions: Drug: Amantadine
Drug: Modafinil
Drug: Methylphenidate
Drug: Placebos

First Posted Date: 2017-06-14

Last Posted Date: 2020-10-20

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 141

Registration Number: NCT03185065

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Amantadine and Functional Improvement Following ABI Measured by MRI Tractography; A Pilot Study

Not Applicable

Conditions: Coma
Persistent Vegetative State
Acquired Brain Injury
Traumatic Brain Injury
Minimally Conscious State

Interventions: Drug: Amantadine
Procedure: MRI Tractography Study

First Posted Date: 2015-10-02

Last Posted Date: 2015-12-11

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 10

Registration Number: NCT02566720

Locations: 🇨🇦
Hamilton Health Sciences, Hamilton, Ontario, Canada

Amantadine to Speed Awakening After Cardiac Arrest

Phase 2

Completed

Conditions: Heart Arrest
Coma
Anoxia

Interventions: Drug: Placebo
Drug: Amantadine

First Posted Date: 2015-07-01

Last Posted Date: 2019-12-04

Lead Sponsor: Jon Rittenberger, MD

Target Recruit Count: 14

Registration Number: NCT02486211

Locations: 🇺🇸
Main Medical Center, Portland, Maine, United States
🇺🇸
Beth Israel Deacconness, Boston, Massachusetts, United States
🇺🇸
UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States

and more 1 locations

Acetylamantadine Excretion by Cancer Patients

Conditions: Cancer

Interventions: Drug: Amantadine

First Posted Date: 2014-10-29

Last Posted Date: 2021-03-17

Lead Sponsor: University of Manitoba

Target Recruit Count: 120

Registration Number: NCT02277938

Locations: 🇨🇦
St. Boniface Hospital, Winnipeg, Manitoba, Canada

Amantadine + rTMS as a Neurotherapeutic for Disordered Consciousness

Not Applicable

Completed

Conditions: Traumatic Brain Injury

Interventions: Device: rTMS
Drug: Amantadine

First Posted Date: 2014-01-01

Last Posted Date: 2020-08-24

Lead Sponsor: Edward Hines Jr. VA Hospital

Target Recruit Count: 4

Registration Number: NCT02025439

Locations: 🇺🇸
Edward Hines, Jr. VA Hospital, Hines, Illinois, United States
🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States

Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease

Phase 2

Terminated

Conditions: Idiopathic Parkinson's Disease
Drug Induced Dyskinesia

Interventions: Drug: Placebo
Drug: Topiramate
Drug: Amantadine

First Posted Date: 2013-02-11

Last Posted Date: 2019-04-16

Lead Sponsor: Rush University Medical Center

Target Recruit Count: 42

Registration Number: NCT01789047

Locations: 🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸
Oregon Health Sciences University, Portland, Oregon, United States

and more 2 locations

Efficacy Study of Amantadine to Treat Gait Dysfunction and Freezing in Parkinson's Disease

Phase 3

Terminated

Conditions: Parkinson's Disease

Interventions: Drug: Placebo
Drug: Amantadine

First Posted Date: 2012-07-30

Last Posted Date: 2019-11-13

Lead Sponsor: Northwestern University

Target Recruit Count: 3

Registration Number: NCT01652534

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy